Product Description
CDX-622 targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation. Combined neutralization of SCF and TSLP with CDX-622 is expected to simultaneously reduce tissue mast cells and inhibit Type 2 inflammatory responses to potentially offer enhanced therapeutic benefit in inflammatory and fibrotic disorders. (Sourced from: https://ir.celldex.com/news-releases/news-release-details/celldex-reports-second-quarter-2024-financial-results-and)
Mechanisms of Action: TSLP Inhibitor,C-Kit Inhibitor
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Celldex
Company Location: HAMPTON NJ 08827
Company CEO: Anthony S. Marucci
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Inflammation
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|